Mercer Global Advisors
APGE

Mercer Global Advisors’s Apogee Therapeutics APGE Stock Holding History

Mercer Global Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125M Buy
941,283
+109,855
+13% +$9.9M 0.15% 87
2026
Q1 		$70M Sell
831,428
-59,237
-7% -$4.3M 0.1% 115
2025
Q4 		$67.2M Sell
890,665
-79,916
-8% -$5.03M 0.1% 122
2025
Q3 		$38.6M Buy
970,581
+150,205
+18% +$5.74M 0.06% 182
2025
Q2 		$35.6M Sell
820,376
-819,804
-50% -$31.2M 0.07% 154
2025
Q1 		$61.3M Buy
1,640,180
+920,079
+128% +$35.6M 0.14% 87
2024
Q4 		$32.6M Buy
+720,101
New +$36.7M 0.08% 138

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Mercer Global Advisors's APGE Position: Q2 2026 in Review

Mercer Global Advisors increased its Apogee Therapeutics (APGE) stake by 13% in Q2 2026, buying an estimated $9.9M and bringing the position to 941,283 shares worth $125M. The position accounts for 0.15% of the portfolio, ranked #87.

Mercer Global Advisors first reported a position in APGE in Q4 2024 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Mercer Global Advisors held 941,283 shares of Apogee Therapeutics worth $125M as of Q2 2026.
  • Mercer Global Advisors bought 109,855 Apogee Therapeutics shares in Q2 2026, an estimated $9.9M.
  • Apogee Therapeutics made up 0.15% of Mercer Global Advisors's portfolio in Q2 2026, its #87 holding.
  • Mercer Global Advisors first reported a position in Apogee Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.